(secondQuint)A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.

3 mg for the Treatment of Hot Flashes.

 The overall study duration will be approximately 16 weeks.

 After a screening/baseline period of up to 4 weeks patients will be randomized to receive either placebo tablets or Cenestin 0.

3mg tablets.

 A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.

3 mg for the Treatment of Hot Flashes@highlight

This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.

3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.

